Renal cell carcinoma accounts for about 3% of all adult cancers and is also the most common of kidney cancers (90-95%) affecting mostly men, between the ages 50-70 years.
Renal cell carcinoma is commonly seen to affect North Americans and those of Scandinavian ancestry more often than it affects people of Asian or African descent. In the United States, Blacks are more affected than the Whites. Also, the incidence in men is greater than that seen in women. Although the disease is usually detected after age 50, it is seen to occur in young people too who have a family predisposition.
Renal cell carcinoma (RCC) is known for its lack of early symptoms and resistance to treatments such as chemo and radio therapy. However, of late, it has been noticed that these cancers are being detected early and managed through treatments such as thermal ablation, nephron –sparing surgeries, with radical nephrectomy (removal of the kidney and surrounding structures) being the gold standard in treating central and large tumors. Also, targeted therapy is being effectively applied in those with metastatic disease, where the cancer has spread to other parts of the body.
Latest Publications and Research on Renal Cell CarcinomaHIF Stimulates Reductive Glutamine Metabolism in Renal Cell Carcinoma. - Published by PubMed
Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma. - Published by PubMed
Effect of different breathing patterns in the same patient on stereotactic ablative body radiotherapy dosimetry for primary renal cell carcinoma: A case study. - Published by PubMed
Impact of lymphadenectomy in management of renal cell carcinoma. - Published by PubMed
Sunitinib induced nephrotic syndrome and thrombotic microangiopathy. - Published by PubMed